1. Bates SE, Regis JI, Robey RW, Zhan Z, Scala S, Meadows BJ. Chemoresistance in the clinic: overview 1994. Bull Cancer. 1994;81(Suppl 2):55s–61s.
2. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS, Muschel RJ. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002;8:885–92.
3. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948–56.
4. Mansouri A, Henle KJ, Nagle WA. Tumor drug-resistance: a challenge to therapists and biologists. Am J Med Sci. 1994;307:438–44.
5. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 2004;9(Suppl 5):31–40.